ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has announced the online availability of an interview conducted by leading investor information website service WallSt.net with President, Dr. Mark Landy, in which he discussed the Company’s recently released test results showing that merging Biosync Scientific’s certified bare metal stent platform, which MIVT recently acquired, with the Company’s polymer-free drug delivery system met critical FDA requirements for in vitro mechanical fatigue testing.
